Ecomax, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023
February 09, 2024 at 03:27 pm
Share
Ecomax, Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported sales was USD 0.150493 million. Net loss was USD 0.011013 million compared to USD 0.031052 million a year ago.
For the six months, sales was USD 0.362178 million. Net loss was USD 0.023264 million compared to USD 0.059823 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.
Ecomax, Inc. is engaged in selling and distributing Rocitin NMN products to customers in the Territory. Rocitin NMN is a nutritional supplement manufactured by Pharmazeutische Fabrik Evers GmbH & Co. KG, a German company. Each bottle contains 60 capsules, 10080 mg of NMN. NMN, as β-Nicotinamide Mononucleotide exists in some fruits, vegetables, and poultry. It is a molecule naturally occurring in all life forms and can be transformed into a significant coenzyme NAD+ within cells, which is important to human metabolism. Its research, including Nicotinamide mononucleotide (NMN) as an anti-aging health product has shown that NAD+ levels in the body will decrease with age, and that exogenous supplementation of NMN enhances NAD+ levels and thus the function of human cells. In addition, NMN also helps to repair broken DNA, regulate the stability of DNA and cell death, and improve neurodegenerative and metabolic conditions.
ECOMAX, INC. 